摘要
目的探讨慢性肝炎患者应用胸腺五肽后对外周血T细胞亚群水平变化的影响效果。方法 60例慢性肝炎患者,通过随机信封法分为对照组和试验组,各30例。对照组采用综合治疗方案,试验组在对照组基础上联合胸腺五肽治疗,观察两组患者治疗前后T细胞亚群CD3+、CD4+、CD4+/CD8+变化情况。结果治疗后,试验组T细胞亚群CD3+(70.11±10.25)%、CD4+(51.89±11.17)%、CD4+/CD8+(1.49±0.53)水平明显高于对照组的(65.52±10.12)%、(44.56±10.11)%、(1.38±0.64),CD8+(21.16±2.71)%水平低于对照组的(24.47±3.62)%,差异均有统计学意义(P<0.05)。结论胸腺五肽药物可促进慢性肝炎患者T细胞CD4+、CD8+的成熟及分化水平,增强细胞毒性T细胞(Tc细胞)、辅助性T细胞(Th细胞)活性,改善肝脏细胞抗感染能力及修复、抗纤维化能力,胸腺五肽与T细胞特异性受体结合增强细胞内反应,调节机体免疫水平,抑制肝脏细胞对炎性因子的刺激作用,改善预后并降低复发率,临床疗效优异,值得临床推广。
Objective To discuss the effect of thymopentin on changes of peripheral blood T cell subsets in patients with chronic hepatitis.Methods A total of 60 patients with chronic hepatitis were divided by random envelope method into control group and experimental group,with 30 cases in each group.The control group received comprehensive treatment regime,and the experimental group received thymopentin treatment on the basis of the control group.Observation were made on changes of T cell subsets CD3+,CD4+and CD4+/CD8+before and after treatment between the two groups.Results After treatment,the experimental group had obviously higher T cell subsets CD3+as(70.11±10.25)%.CD4+as(51.89±11.17)%and CD4+/CD8+as(1.49±0.53)than(65.52±10.12)%,(44.56±10.11)%and(1.38±0.64)in the control group,and lower CD8+as(21.16±2.71)%than(24.47±3.62)%in the control group.Their difference was statistically significant(P<0.05).Conclusion Thymopentin can promote the maturation and differentiation of T cell CD4+and CD8+T cells in patients with chronic hepatitis,enhance the activity of cytotoxic T cells(Tc cells)and T helper cells(Th cells),improve the ability of anti-infective,repair and anti-fibrosis of liver cells.Combination of thymopentin and T cell-specific receptors can enhance intracellular responses,regulate immunity,inhibit the stimulation of inflammatory cytokines in liver cells,improve prognosis and reduce the recurrence rate.The clinical efficacy is excellent and worthy of clinical promotion.
作者
杨杰
YANG Jie(Fushun Infectious Diseases Hospital,Fushun 113015,China)
出处
《中国现代药物应用》
2018年第6期19-21,共3页
Chinese Journal of Modern Drug Application
